①The Lancet：Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial

临床试验：阿片类镇痛药物用于急性腰痛和颈痛(OPAL试验):一项随机安慰剂对照试验

(相关资料图)

DOI: 10.1016/S0140-6736(23)00404-X

②The Lancet：Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

临床试验：GIP、GLP-1和胰高血糖素受体激动剂Retatrutide用于2型糖尿病患者的随机、双盲、安慰剂和活性药对照、平行组、Ⅱ期试验

DOI: 10.1016/S0140-6736(23)01053-X

③The Lancet：Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

临床试验：GLP-1受体激动剂Tirzepatide用于2型糖尿病患者肥胖(SURMOUNT-2)的一项双盲、随机、多中心、安慰剂对照的Ⅲ期试验

DOI: 10.1016/S0140-6736(23)01200-X

④The Lancet Infectious Diseases：Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

临床试验：纯化灭活寨卡病毒候选疫苗在接种日本脑炎病毒或黄热病病毒疫苗的成人中的安全性和免疫原性:美国一项1期、随机、双盲、安慰剂对照临床试验

DOI: 10.1016/S1473-3099(23)00192-5

⑤EClinicalMedicine：Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

临床研究：卡瑞利珠单抗联合法米替尼用于接受PD-1阻断策略的复发或转移性鼻咽癌患者:一项多队列Ⅱ期研究的数据

DOI: 10.1016/j.eclinm.2023.102043

⑥Journal of Biomolecular Structure and Dynamics：An insight into structure-activity relationship of naturally derived biological macromolecules for the treatment of Alzheimer"s disease: a review

综述：天然来源的生物大分子用于阿尔茨海默病的构效关系研究进展

DOI: 10.1080/07391102.2023.2230279

⑦靶向作用于包括非小细胞肺癌在内的晚期实体瘤ROS1和NTRK致癌因子的新一代激酶抑制剂瑞普替尼（repotrectinib）的新药上市申请获国家药品监督管理局（NMPA）受理

⑧抗BTLA单抗Tifcemalimab联合特瑞普利单抗用于局限期小细胞肺癌的III期临床研究获美国食品药品监督管理局（FDA）批准

⑨FcRn抗体巴托利单抗（HBM9161）用于全身型重症肌无力（gMG）的上市申请获CDE受理

⑩人源化的高亲和力抗人新生儿 Fc 受体 (FcRn) 单克隆抗体 (IgG4P)Rozanolixizumab获FDA批准上市，用于乙酰胆碱受体抗体或肌肉特异性酪氨酸激酶抗体阳性成人全身性重症肌无力（gMG）

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！

标签：